The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...

A Cochrane systematic review has found new moderate-quality evidence that tiotropium + long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS) combination therapy reduces hospital admission for ...

FLAME analysis suggests COPD exacerbation risk spikes for 3 months after stopping LAMA or ICS, underscoring adherence and careful step-down.

Please provide your email address to receive an email when new articles are posted on . Moving from a low-dose inhaled corticosteroid to a medium-dose inhaled corticosteroid plus a long-acting beta ...

When added to ICS, tiotropium and LABAs perform similarly for asthma patients. What is the effect of ICS/LABA controller therapy on asthma in patients with persistent cold airway hyperresponsiveness, ...

For patients with moderate to severe chronic obstructive pulmonary disease (COPD), treatment options include a long-acting beta-agonist (LABA) alone or a LABA combined with an inhaled corticosteroid ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved updates to the SYMBICORT ® (budesonide ...

Please provide your email address to receive an email when new articles are posted on . Fluticasone-based inhaled corticosteroid treatment substantially changed airway microbiome diversity in patients ...

Additional data presentations for fluticasone furoate and vilanterol trifenatate support the potential of developmental combination treatment, Relovair, in COPD and asthma LONDON and SOUTH SAN ...